Nordhealth AS

Nordhealth AS has a strong liquidity position with a current ratio of 2.21, indicating the company can cover its short-term liabilities with its current assets. The company holds EUR 14.7 million in cash and equivalents, which is a significant portion of its total assets of EUR 71.5 million. However, the company's free cash flow is negative at EUR -6.5 million, driven by capital expenditures of EUR -5.1 million. Profitability metrics show a challenging financial position for Nordhealth AS. The company reported a net loss of EUR -12.7 million and an operating loss of EUR -12.5 million in the latest period. Return on equity is negative at -20.6%, and return on assets is also negative at -17.7%. These figures are below the industry median for profitability metrics, indicating that Nordhealth AS is underperforming relative to its peers in the Advanced Medical Equipment & Technology industry. Geographically, Nordhealth AS is primarily focused on the Nordic region, with a significant portion of its EUR 50.8 million in revenue derived from Norway. The company has limited international exposure, which could pose a concentration risk if the Norwegian market experiences economic downturns or regulatory changes. Looking ahead, Nordhealth AS is expected to maintain a stable revenue trajectory, with no significant growth or decline projected in the next fiscal year. The company's capital expenditures are expected to remain at current levels, and there are no immediate signs of aggressive expansion or contraction in the business. The risk assessment for Nordhealth AS indicates a low level of liquidity risk, supported by its strong cash position and absence of long-term debt. However, the company's negative operating and net income raise concerns about its ability to sustain operations without external financing. The risk of dilution is also low, as there are no immediate filing-based flags indicating potential share dilution. Recent events and filings for Nordhealth AS show a consistent financial position with no major changes in the company's capital structure or operations. The company has not issued new shares or taken on additional debt in the latest reporting period. Analysts have a strong buy rating for the stock, with a mean price target of EUR 33.00, suggesting confidence in the company's long-term prospects despite its current financial challenges.